Receptor, ErbB-2

"Receptor, ErbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.

Descriptor ID	D018719
MeSH Number(s)	D08.811.913.696.620.682.725.400.009.400 D12.776.543.750.630.009.400 D12.776.543.750.750.400.074.400 D12.776.624.664.700.642 D23.050.301.500.600.700 D23.050.705.552.600.550 D23.101.140.642
Concept/Terms	Receptor, ErbB-2 Receptor, ErbB-2 ErbB-2 Receptor Antigens, CD340 CD340 Antigens Proto-Oncogene Proteins c-erbB-2 Proto Oncogene Proteins c erbB 2 p185(c-neu) c-erbB-2 Protein c erbB 2 Protein erbB-2 Proto-Oncogene Protein Proto-Oncogene Protein, erbB-2 erbB 2 Proto Oncogene Protein erbB-2 Receptor Protein-Tyrosine Kinase erbB 2 Receptor Protein Tyrosine Kinase neu Proto-Oncogene Protein Proto-Oncogene Protein, neu neu Proto Oncogene Protein HER-2 Proto-Oncogene Protein HER 2 Proto Oncogene Protein Proto-Oncogene Protein, HER-2 Proto-Oncogene Protein HER-2 Proto Oncogene Protein HER 2 Receptors, erbB-2 erbB-2 Receptors Neu Receptor Receptor, Neu Metastatic Lymph Node Gene 19 Protein Proto-oncogene Protein Neu Neu, Proto-oncogene Protein Proto-oncogene c-ErbB-2 c-ErbB-2, Proto-oncogene Tyrosine Kinase-type Cell Surface Receptor HER2 Tyrosine Kinase type Cell Surface Receptor HER2 p185erbB2 Protein CD340 Antigen Oncogene Protein HER-2 Oncogene Protein HER 2 Proto-Oncogene Protein p185(neu)

Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-2".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
ErbB Receptors [D08.811.913.696.620.682.725.400.009]
Receptor, ErbB-2 [D08.811.913.696.620.682.725.400.009.400]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
ErbB Receptors [D12.776.543.750.630.009]
Receptor, ErbB-2 [D12.776.543.750.630.009.400]
Receptors, Peptide [D12.776.543.750.750]
Receptors, Growth Factor [D12.776.543.750.750.400]
ErbB Receptors [D12.776.543.750.750.400.074]
Receptor, ErbB-2 [D12.776.543.750.750.400.074.400]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
Receptor, ErbB-2 [D12.776.624.664.700.642]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Histocompatibility Antigens [D23.050.301.500]
Minor Histocompatibility Antigens [D23.050.301.500.600]
Receptor, ErbB-2 [D23.050.301.500.600.700]
Isoantigens [D23.050.705]
Histocompatibility Antigens [D23.050.705.552]
Minor Histocompatibility Antigens [D23.050.705.552.600]
Receptor, ErbB-2 [D23.050.705.552.600.550]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]
Receptor, ErbB-2 [D23.101.140.642]

Below are MeSH descriptors whose meaning is related to "Receptor, ErbB-2".

Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-2".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptor, ErbB-2" by people in this website by year, and whether "Receptor, ErbB-2" was a major or minor topic of these publications.

Bar chart showing 45 publications over 19 distinct years, with a maximum of 5 publications in 2009 and 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
2000	1	1	2
2004	1	0	1
2006	1	0	1
2007	2	1	3
2008	0	1	1
2009	2	3	5
2010	0	2	2
2011	0	1	1
2012	1	4	5
2013	1	2	3
2014	0	2	2
2015	1	1	2
2017	1	2	3
2019	1	2	3
2020	2	1	3
2021	1	1	2
2022	0	2	2
2024	3	0	3

Below are the most recent publications written about "Receptor, ErbB-2" by people in Profiles.

Avelino ARM, Pulipati S, Jamouss K, Bhardwaj PV. Updates in Treatment of HER2-positive Metastatic Breast Cancer. Curr Treat Options Oncol. 2024 Dec; 25(12):1471-1481.

View in: PubMed
Bhardwaj PV, Abdou Y. Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies. J Clin Oncol. 2024 Dec; 42(34):4012-4017.

View in: PubMed
Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon a-accelerated murine lupus. Int Immunopharmacol. 2024 Oct 25; 140:112692.

View in: PubMed
Ling AY, Jreich R, Montez-Rath ME, Meng Z, Kapphahn K, Chandross KJ, Desai M. Transporting observational study results to a target population of interest using inverse odds of participation weighting. PLoS One. 2022; 17(12):e0278842.

View in: PubMed
Perez EA, Dang C, Lee C, Singh J, Wang K, Layton JB, Gilsenan A, Hackshaw MD, Cortes J. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Breast Cancer Res Treat. 2022 Jul; 194(1):1-11.

View in: PubMed
Murthy SRK, Cheng X, Zhuang T, Ly L, Jones O, Basadonna G, Keidar M, Canady J. BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer. Sci Rep. 2022 03 08; 12(1):4038.

View in: PubMed
Ersoy E, Cao QJ, Otis CN. HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas. Int J Gynecol Pathol. 2022 07 01; 41(4):313-319.

View in: PubMed
Liu B, Singh K, Gong S, Canakci M, Osborne BA, Thayumanavan S. Protein-Antibody Conjugates (PACs): A Plug-and-Play Strategy for Covalent Conjugation and Targeted Intracellular Delivery of Pristine Proteins. Angew Chem Int Ed Engl. 2021 06 01; 60(23):12813-12818.

View in: PubMed
Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P, Mitchell JD, Nohria A, Fradley MG, Pusic I, Stockerl-Goldstein K, Blaes A, Lyon AR, Ganatra S, L?pez-Fern?ndez T, O'Quinn R, Minotti G, Szmit S, Cardinale D, Alvarez-Cardona J, Curigliano G, Neilan TG, Herrmann J. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. CA Cancer J Clin. 2020 11; 70(6):480-504.

View in: PubMed
Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Rev Anticancer Ther. 2020 09; 20(9):755-763.

View in: PubMed

People

Explore

Similar Concepts

Top Journals